Novel KAT6B::NUTM2B fusion oncogene in congenital acute myeloid leukemia and implications for menin inhibitor therapy

Key Points

• The research aims to identify the KAT6B::NUTM2B fusion oncogene and explore its therapeutic implications.
• Identified KAT6B::NUTM2B fusion through genomic analysis.
• Evaluated the role of menin inhibitors in treating leukemia associated with the fusion.
• Demonstrated the presence of KAT6B::NUTM2B fusion in congenital acute myeloid leukemia.
• Indicated potential effectiveness of menin inhibitors in targeting the fusion-driven pathology.